Clas Rehnberg

Clas Rehnberg

Auto-generated profile, based on publicly available information

Clas Rehnberg

Karolinska Institutet

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2005 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
FBFredrik Borgström
Fredrik Borgström
NZNiklas Zethraeus
Niklas Zethraeus
OJOlof Johnell
Olof Johnell
LLLars Lidgren
Lars Lidgren
SPSari Ponzer
Sari Ponzer
BJBengt Jönsson
Bengt Jönsson

28 April 2007 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
MLMathias Lidgren
Mathias Lidgren
NWNils Wilking
Nils Wilking
BJBengt Jönsson
Bengt Jönsson
CRClas Rehnberg
Clas Rehnberg

1 June 2006
Verified
Journal Article
Closed access
PSPatrik Sobocki
Patrik Sobocki
BJBengt Jonsson
Bengt Jonsson
JAJules Angst
Jules Angst
CRClas Rehnberg
Clas Rehnberg

18 July 2006 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
FBF. Borgström
F. Borgström
OJO. Johnell
O. Johnell
JKJ. A. Kanis
J. A. Kanis
BJB. Jönsson
B. Jönsson
CRC. Rehnberg
C. Rehnberg

6 December 2007 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
MLM. Lidgren
M. Lidgren
BJB. Jönsson
B. Jönsson
CRC. Rehnberg
C. Rehnberg
NWN. Willking
N. Willking
JBJ. Bergh
J. Bergh
Background: Clinical studies have demonstrated statistically significant reduction of breast cancer relapse and improved overall survival by adding trastuzumab for 1 year after adjuvant chemotherapy in human epidermal growth factor receptor-2 protein (HER2)/neu-positive breast cancer. The aim of this study was to analyze the cost-effectiveness of HER2/neu testing and the addition of 1-year adjuvant trastuzumab after adjuvant chemotherapy from a societal perspective in a Swedish setting. Material and methods: We used a Markov state transition model to simulate HER2/neu testing and adjuvant trastuzumab treatment in a hypothetical cohort of early breast cancer patients. Results: The cost per quality adjusted life year (QALY) gained for immunohistochemical (IHC) testing for all patients with FISH confirmation of IHC 2+ and 3+ and 1-year adjuvant trastuzumab for FISH-positive patients was estimated to € 36 000. The strategy of FISH testing for all patients, with 1-year adjuvant trastuzumab for FISH-positive patients was associated with the longest quality adjusted survival of all evaluated treatment strategies and the cost per QALY gained was estimated to € 41 500. The remaining testing and treatment strategies were dominated. Conclusion: FISH testing for all patients with 1-year adjuvant trastuzumab for FISH+ patients is a cost-effective treatment option from a societal perspective.

1 May 2005 in Health Policy and Planning
Verified
Journal Article
Open access
PDF file
QMQingyue Meng
Qingyue Meng
GCGang Cheng
Gang Cheng
LSLynn Silver
Lynn Silver
XSXiaojie Sun
Xiaojie Sun
CRClas Rehnberg
Clas Rehnberg
GTGöran Tomson
Göran Tomson
In China, 44.4% of total health expenditures in 2001 were for pharmaceuticals. Containment of pharmaceutical expenditures is a top priority for policy intervention. Control of drug retail prices was adopted by the Chinese government for this purpose. This study aims to examine the impact of this policy on the containment of hospital drug expenditures, and to analyze contributing factors. This is a retrospective pre/post-reform case study in two public hospitals. Financial records were reviewed to analyze changes in drug expenditures for all patients. A tracer condition, cerebral infarction, was selected for in-depth examination of changes in prices, utilization, expenditures and rationality of drugs. In the two hospitals, a total of 104 and 109 cerebral infarction cases, hospitalized respectively before and after the reform, were selected. Prescribed daily dose (PDD) was used for measuring drug utilization, and the contribution of price and utilization to changes in drug expenditures were decomposed. Rationality of drug use post-reform was reviewed based on published literature. Drug expenditures for all patients still increased rapidly in the two hospitals after implementation of the pricing policy. In the provincial hospital, drug expenditures per patient for cerebral infarction cases declined, but not significantly. This was mainly attributable to reduced utilization. In the municipal hospital, drug expenditure per patient increased by 50.1% after the reform, mainly due to greater drug utilization. Three to five fold higher drug expenditure per inpatient day in the provincial hospital was due to use of more expensive drugs. Of the top 15 drugs for treating cerebral infarction cases after the reform, 19.5% and 46.5% of the expenditures, in the provincial and municipal hospitals, respectively, were spent on drugs with prices set by the government. A large proportion of expenditures for the top 15 drugs, at least 65% and 41% in the provincial and municipal hospitals, respectively, was spent on allopathic drugs without an adequate evidence base of safety and efficacy supporting use for cerebral infarction. Control of retail prices, implemented in isolation, was not effective in containing hospital drug expenditures in these two Chinese hospitals. Utilization, more than price, determined drug expenditures. Improvement of rational use of drugs and correcting the present incentive structure for hospitals and drug prescribers may be important additional strategies for achieving containment of drug expenditures.